Scientific Advisory Board

Kristina Burow is a Principal with ARCH, joining the firm in 2004. She is primarily focused on companies in the life sciences and materials sciences. Ms. Burow joined ARCH from the Novartis BioVenture Fund in San Diego where she was involved in numerous investments in the life science sector. Previously, as an early employee at the Genomics Institute of the Novartis Research Foundation (GNF), she directed Chemistry Operations and was active in Business Development. She was a co-inventor of key technology platforms that formed the core of Kalypsys, a GNF spin-off company. Ms. Burow is on the board of Sapphire Energy and works actively with Ensemble Discovery, Achaogen, Kythera Biopharmaceuticals, Celula, and Accelerator. Ms. Burow holds an M.B.A. from The University of Chicago, an M.A. in Chemistry from Columbia University, and a B.S. in Chemistry from the University of California, Berkeley.

Nathaniel David, is Chief Science Officer and co-founder of Kythera. As the co-founder of Syrrx (acquired by Takeda for $270 million in 2005) and Achaogen, he has experience creating and growing innovative biotechnology companies. Dr. David was named one of the Top 100 innovators in the world under 35 (2002) by the MIT Technology Review. He holds numerous pending and issued patents in fields such as nanovolume crystallography, antibiotic resistance, and aesthetic medicine. He sits on the executive board of the College of Letters and Sciences, University of California, Berkeley and is a member of the board of trustees of the UC Foundation. He holds a PhD from UC Berkeley in Molecular and Cellular Biology and an AB in Biology from Harvard College.

Steven Goldby joined Venrock in 2007 after spending nine years as CEO of Venrock-backed materials science company, Symyx Technologies, where he is currently Executive Chairman. Mr. Goldby has served as the CEO of MDL Information Systems, a leading scientific information company, before its sale to Reed Elsevier. Prior to MDL, he held various management positions at Alza Corporation (acquired by Johnson and Johnson), including President of Alza Pharmaceuticals. Mr. Goldby was also President of Dynapol, a specialty chemical company and is a registered patent attorney. Mr. Goldby serves on the board of Intermolecular, Inc. Previously, he served on the boards of Vitae Pharmaceuticals (a Venrock-backed company), Ilypsa (acquired by Amgen), Affymax (acquired by GSK), Scios (acquired by Johnson and Johnson), PeopleSoft (acquired by Oracle), Aspect Development (acquired by Itwo), TGV (acquired by Cisco), One Touch Systems (acquired by Apollo Group), Scientific Software (acquired by Agilent). Mr. Goldby is director of Orecon Ltd and Sunesis Pharmaceuticals and Chairman of Nanosys Inc.

Robert Nelsen is a co-founder and a Managing Director of ARCH Venture Partners. He focuses on biotechnology, pharmaceuticals, and nanotechnology. Mr. Nelsen joined ARCH at its founding and has played a significant role in the early sourcing, financing and development of more than thirty companies including Ikaria, Adolor (ADLR), Aviron (AVIR, acquired by Medimmune-MEDI), Caliper Life Sciences (CALP), Illumina (ILMN), Trubion Pharmaceuticals (TRBN), Array BioPharma (ARRY), NetBot, deCODE Genetics (DCGN), Nanosys, Alnylam Pharmaceuticals (ALNY), XenoPort (XNPT), GenVec (GNVC), R2 Technology (acquired by Hologic-HOLX), IDUN Pharmaceuticals (acquired by Pfizer-PFE), Genomica (GNOM, acquired by Exelixis-EXEL), Surface Logix, NeurogesX (NGSX), Classmates.com (acquired by United Online-UNTD), Nura (acquired by Omeros), Kythera Biopharmaceuticals, Elixir Pharmaceuticals, Spaltudaq, VLST, Ensemble Discovery, Accelerator, Apoptos, Fate Therapeutics, Agios Therapeutics, and Everyday Learning.

Mr. Nelsen is a director of Sapphire Energy, Ikaria, Agios, NeurogesX, and Kythera Biopharmaceuticals. He previously served on the boards of Trubion Pharmaceuticals, Surface Logix, NetBot, Everyday Learning, Spaltudaq, Array BioPharma, Caliper Life Sciences, Illumina, R2 Technology, and Classmates.com, among others. He also serves as a director of the Fred Hutchinson Cancer Research Institute. Mr. Nelsen holds an M.B.A. from The University of Chicago and a B.S. in Economics and Biology from the University of Puget Sound.

Jason Pyle was formerly Chief Technical Officer and co-founder of Epoc, Inc., a privately held medical engineering company. Dr. Pyle holds an appointment as adjunct professor of bioengineering at Vanderbilt University where he has worked to develop cross-disciplinary programs of biological and engineering research. As the co-founder and Chief Technical Officer of Pria Diagnostics, Dr. Pyle was named Innovator of the Year (2006) by Frost and Sullivan. Dr. Pyle holds numerous pending and issued patents in the engineering and biological sciences and has worked in diverse cross-discipline areas such as nanofabrication, optical engineering, and structural biology.

In addition to his broad technical abilities, Dr. Pyle has established numerous corporate partnerships between small technical companies and some of the world’s largest corporations. He has directly supervised and coordinated both business development and operational activities within large co-development partnerships. Dr. Pyle has worked directly in finance, technical and manufacturing transactions in Singapore, Japan, and China. His post- doctoral research focused on the large-scale expression and control of neural proteins. He holds a Ph.D. in Molecular and Cellular Physiology and an M.D. from Stanford University. He received degrees in optical engineering and physics from the University of Arizona.

Board Observer Clinton Bybee is a co-founder and Managing Director of ARCH Venture Partners. Mr. Bybee concentrates primarily on advanced materials, electronics, semiconductors, photonics, and infrastructure businesses. Mr. Bybee has helped organize and finance numerous companies including MicroOptical Devices (acquired by EMCORE), Cambrios Technologies, Aveso, Innovalight, Intelligent Reasoning Systems (acquired by Photon Dynamics), Semprius, Nanosys, and Xtera Communications. He is a board member of Impinj, Innovalight, Cambrios Technologies, Xtera Communications, Nitronex and Aveso. Mr. Bybee is an organizing member of the Texas Venture Capital Association and currently serves as its first President. Previously, Mr. Bybee worked with ARCH Development Corporation. He also managed a venture investment fund for the State of Illinois and was a production engineer with Amoco Corporation. Mr. Bybee holds an M.B.A. from the University of Chicago and a B.S. in Engineering from Texas A&M University.